The original rise of Viagra presented a massive opportunity for investors , but its period has expired , creating a complex landscape. Alternative versions have entered the space , cutting into revenues and putting pressure on profit yields. While established healthcare companies continue a foothold in this area, the potential looks ambiguous by in